News
Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...
BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...
Zacks Investment Research on MSN1d
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global ...
BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...
Stocktwits on MSN5d
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer DrugShares of BionNTech SE (BNTX) jumped 13% in Monday’s pre-market after the company announced that it has entered into an ...
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones ...
Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...
Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
GlobalData on MSN4d
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drugBristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...
BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback